Brought to you by 
Megapharm gets Israeli rights to Pharming's Ruconest
11 Jul 2011
Executive Summary
Megapharm Ltd. (private biotech marketing company in Israel) has licensed Israeli rights to Pharming Group NV’s Ruconest (conestat; recombinant human C1 inhibitor) for acute angioedema attacks in hereditary angioedema patients.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
- Transgenics
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Megapharm gets Israeli rights to Pharming's Ruconest
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice